Alexander Popov, Guenter Henze, Grigory Tsaur, Oleg Budanov, Julia Roumiantseva, Mikhail Belevtsev, Tatiana Verzhbitskaya, Liudmila Movchan, Svetlana Lagoyko, Liudmila Zharikova, Yulia Olshanskaya, Tatiana Riger, Alena Valochnik, Natalia Miakova, Dmitry Litvinov, Olga Khlebnikova, Olga Streneva, Elena Stolyarova, Natalia Ponomareva, Galina Novichkova, Olga Aleinikova, Larisa Fechina, Alexander Karachunskiy
BACKGROUND: Quantitative measurement of minimal residual disease (MRD) is the "gold standard" for estimating the response to therapy in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Nevertheless, the speed of the MRD response differs for different cytogenetic subgroups. Here we present results of MRD measurement in children with BCP-ALL, in terms of genetic subgroups with relation to clinically defined risk groups. METHODS: A total of 485 children with non-high-risk BCP-ALL with available cytogenetic data and MRD studied at the end-of-induction (EOI) by multicolor flow cytometry (MFC) were included...
April 2024: Cancer Medicine